Skip to content
Bending the Curve Trial by Trial
?

GOG 85

Fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes (Gynecologic Oncology Group and Southwest Oncology Group study)

N = 388

Population
Biopsy-proven invasive squamous-cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the uterine cervix, FIGO stage IIB, III or IVA, with negative cytologic washings and negative para-aortic lymph nodes
Design
Randomised comparison, protocol activated in 1986: whole-pelvic radiotherapy with concurrent infusional fluorouracil and bolus cisplatin versus the same radiotherapy with oral hydroxyurea. 388 patients were randomised, 368 were eligible (177 to fluorouracil plus cisplatin, 191 to hydroxyurea).
Arms
  • Radiotherapy with fluorouracil and cisplatin (experimental, n = 177): Whole-pelvic radiotherapy with concurrent fluorouracil infusion and bolus cisplatin
  • Radiotherapy with hydroxyurea (control, n = 191): Whole-pelvic radiotherapy with oral hydroxyurea
People
Whitney CW, senior author Liao SY, Gynecologic Oncology Group and Southwest Oncology Group
Primary publication: Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339-48. PubMedDOI

Appears in

Sources

  1. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339-48.

    PubMedDOI